Wellington Management Group LLP Trims Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Wellington Management Group LLP lowered its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 50.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 504,687 shares of the company's stock after selling 523,551 shares during the quarter. Wellington Management Group LLP owned about 1.19% of SI-BONE worth $7,076,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of SIBN. Virtus Fund Advisers LLC bought a new position in shares of SI-BONE in the fourth quarter valued at $40,000. Mainstream Capital Management LLC acquired a new stake in shares of SI-BONE in the 4th quarter worth about $53,000. KLP Kapitalforvaltning AS bought a new position in SI-BONE in the 4th quarter valued at about $97,000. Proficio Capital Partners LLC bought a new position in SI-BONE in the 4th quarter valued at about $155,000. Finally, ProShare Advisors LLC acquired a new position in SI-BONE during the 4th quarter valued at about $163,000. Institutional investors and hedge funds own 98.11% of the company's stock.

SI-BONE Stock Performance

Shares of SIBN stock traded up $0.57 during trading on Thursday, hitting $19.06. The company's stock had a trading volume of 1,057,390 shares, compared to its average volume of 380,941. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a market cap of $812.24 million, a PE ratio of -20.72 and a beta of 0.82. The business has a fifty day moving average of $15.90 and a 200-day moving average of $15.42. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $47.29 million for the quarter, compared to analysts' expectations of $45.13 million. As a group, research analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 9,585 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.76, for a total value of $189,399.60. Following the sale, the chief financial officer now directly owns 224,507 shares in the company, valued at $4,436,258.32. The trade was a 4.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. This trade represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,565 shares of company stock worth $1,669,871 over the last three months. 4.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SIBN shares. Needham & Company LLC restated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Truist Financial increased their price target on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.